DEF 14A: Zoetis Seeks Shareholder Approval for Officer Exculpation, Director Elections Highlight 2024 Annual Meeting

Zoetis Inc. is holding its 2024 Annual Meeting of Shareholders on May 22, 2024, to vote on director elections, executive compensation, auditor ratification, officer exculpation, and a shareholder proposal.

Summary

• Zoetis Inc. will hold its 2024 Annual Meeting of Shareholders virtually on May 22, 2024, at 8:00 a.m. EDT.
• Shareholders of record as of March 28, 2024, are entitled to vote on the election of twelve directors, an advisory vote on executive compensation, ratification of KPMG as the independent auditor, an amendment to the Restated Certificate of Incorporation for officer exculpation, and a shareholder proposal regarding director resignation policy.
• The Board recommends voting FOR the election of all director nominees, the advisory vote on executive compensation, the ratification of KPMG, and the amendment to the Restated Certificate of Incorporation.
• The Board recommends voting AGAINST the shareholder proposal regarding the director resignation policy.
• In 2023, Zoetis delivered operational revenue growth and operational adjusted net income growth of 7%.
• The company paid $692 million in dividends and repurchased $1,092 million in Zoetis common stock.
• The Board raised the quarterly dividend by 15% in December 2023, from $0.375 to $0.432.
• Annual Incentive Plan (AIP) payouts for NEOs averaged 117% of target.
• Performance-vesting restricted stock units (performance award units) for the 2021-2023 cycle vested at 97.7% of target, reflecting relative total shareholder return (Relative TSR) performance at the 49th percentile of the S&P 500 Group.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and shareholder returns, but also acknowledges potential risks and uncertainties.

Positives

• Zoetis delivered strong growth and shareholder value in 2023, with operational revenue and adjusted net income growth of 7%.
• The company returned capital to shareholders through dividends of $692 million and share repurchases of $1,092 million.
• The Board increased the quarterly dividend by 15% in December 2023.
• The company has a diverse and experienced Board of Directors with relevant expertise.
• Zoetis has a strong commitment to sustainability and diversity, equity, and inclusion (DE&I).
• The company has a robust director resignation policy in place.
• Zoetis has a clawback policy and a compensation recovery policy in place.

Negatives

• The Board recommends voting AGAINST a shareholder proposal regarding an improvement to the director resignation policy, which may be viewed negatively by some shareholders.
• The company faces geopolitical and economic uncertainties in the world.

Risks

• The company is reliant on complex information systems and digital solutions that make it vulnerable to cyber intrusion and attack.
• The company faces risks related to financial, operational, technological, privacy, cybersecurity, data and physical security, disaster recovery, legal and regulatory matters.
• The company faces risks related to natural resources and climate, manufacturing quality and environmental, health and safety matters.
• The company faces risks associated with its strategy and investments in research and development and external innovation.

Future Outlook

The company is confident in its prospects for continued future growth as the global leader in animal health.

Management Comments

• Driven by our purpose, to nurture our world and humankind by advancing care for animals, our colleagues helped us deliver another year of strong growth and shareholder value in 2023, through game-changing innovation, supply chain improvements and commercial excellence capabilities.
• We are proud of what we have achieved and are confident in our prospects for continued future growth as the global leader in animal health.
• The diversity of Zoetis business across markets, species and therapeutic areas has sustained our performance over time demonstrating that animal health remains durable, resilient and essential even in challenging conditions.

Industry Context

Zoetis operates in the animal health industry, competing with other companies in the pharmaceutical, biotechnology, life sciences, and healthcare equipment industries.

Comparison to Industry Standards

• The compensation peer group used by the Human Resources Committee in determining 2023 executive compensation was comprised of 15 companies including Agilent Technologies, Inc., Illumina, Inc., Baxter International Inc., Intuitive Surgical, Inc., Becton, Dickinson and Company, IQVIA Holdings Inc., Biogen Inc., Mettler-Toledo International Inc., Boston Scientific Corporation, Stryker Corporation, Elanco Animal Health Incorporated, Thermo Fisher Scientific Inc., Gilead Sciences, Inc., Zimmer Biomet Holdings, Inc., and IDEXX Laboratories, Inc.
• Zoetis ranked in the 45th percentile in revenue and 80th percentile in total market capitalization among the companies in the above peer group.

Related Party Transactions

• During fiscal year 2023, we did not enter into any related person transactions.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key proposals that will impact the company's governance and performance.
• Employees are recognized for their contributions to the company's success.
• Customers will benefit from the company's continued innovation and commitment to animal health.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will file a Current Report on Form 8-K with the SEC within four business days following the 2024 Annual Meeting of Shareholders to disclose the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Executive Compensation, Director Election, KPMG, Officer Exculpation, Shareholder Proposal, Corporate Governance, Sustainability, Zoetis